(Q46505377)

22 December 2017

title

Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia (English)

1 reference

22 December 2017

0 references

Viviane Labrie

1

1 reference

22 December 2017

Tatiana Lipina

series ordinal

2

1 reference

22 December 2017

John C Roder

series ordinal

3

1 reference

22 December 2017

publication date

3 July 2008

1 reference

22 December 2017

number of pages

14

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

22 December 2017

volume

200

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

217-230

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s00213-008-1196-6

exact match

0 references

cites work

Cognitive function in schizophrenia: association with negative and positive symptoms.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1196-6

Impaired attention, genetics, and the pathophysiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1196-6

Animal models for the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1196-6

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1196-6

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1196-6

Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits

21 January 2018

1 reference

12 December 2020

Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice

1 reference

12 December 2020

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

1 reference

12 December 2020

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

1 reference

12 December 2020

The pharmacology of latent inhibition as an animal model of schizophrenia

1 reference

12 December 2020

Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1.

1 reference

12 December 2020

Sex differences in the behavioral response to spatial and object novelty in adult C57BL/6 mice

1 reference

12 December 2020

ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter

1 reference

12 December 2020

D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning.

1 reference

12 December 2020

Clinical features of latent inhibition in schizophrenia

1 reference

12 December 2020

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

1 reference

12 December 2020

Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

1 reference

12 December 2020

Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala.

1 reference

12 December 2020

Neurobiology of schizophrenia

1 reference

12 December 2020

Effects of lesions to the glutamatergic afferents to the nucleus accumbens in the modulation of reactivity to spatial and non-spatial novelty in mice.

1 reference

12 December 2020

Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

1 reference

12 December 2020

Mobile NMDA receptors at hippocampal synapses

1 reference

12 December 2020

Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition

1 reference

12 December 2020

Glycine binding primes NMDA receptor internalization

1 reference

12 December 2020

Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site

1 reference

12 December 2020

Polymorphism in the 5'-promoter region of serine racemase gene in schizophrenia

1 reference

12 December 2020

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

1 reference

12 December 2020

Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function

1 reference

12 December 2020

Mice with reduced NMDA receptor expression display behaviors related to schizophrenia

1 reference

12 December 2020

Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts

1 reference

12 December 2020

Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia

1 reference

12 December 2020

Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function

1 reference

12 December 2020

Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia.

1 reference

12 December 2020

Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function

1 reference

12 December 2020

Vasopressin V1b receptor knockout reduces aggressive behavior in male mice

1 reference

12 December 2020

NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity

1 reference

12 December 2020

N‐methyl‐d‐aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case‐control analyses

1 reference

12 December 2020

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

1 reference

12 December 2020

Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex.

1 reference

12 December 2020

Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats.

1 reference

12 December 2020

Involvement of glutamatergic and dopaminergic systems in the reactivity of mice to spatial and non-spatial change.

1 reference

12 December 2020

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

1 reference

12 December 2020

Neurocognitive deficits and social functioning in outpatients with schizophrenia

1 reference

12 December 2020

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

1 reference

12 December 2020

Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

1 reference

12 December 2020

A genetic variant of the serine racemase gene is associated with schizophrenia

1 reference

12 December 2020

Dysfunctions in mice by NMDA receptor point mutations NR1(N598Q) and NR1(N598R)

1 reference

12 December 2020

Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice

1 reference

12 December 2020

SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats

1 reference

12 December 2020

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

12 December 2020

Glutamate and schizophrenia: beyond the dopamine hypothesis

1 reference

12 December 2020

Latent inhibition is disrupted by nucleus accumbens shell lesion but is abnormally persistent following entire nucleus accumbens lesion: The neural site controlling the expression and disruption of the stimulus preexposure effect.

1 reference

12 December 2020

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.

1 reference

12 December 2020

Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients

1 reference

12 December 2020

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

1 reference

12 December 2020

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

1 reference

12 December 2020

The relation between latent inhibition and symptom-types in young schizophrenics.

1 reference

12 December 2020

Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice

1 reference

12 December 2020

Pathophysiologically based treatment interventions in schizophrenia

1 reference

12 December 2020

Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration.

1 reference

12 December 2020

10.1007/S00213-008-1196-6

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

18597079

1 reference

22 December 2017